PT - JOURNAL ARTICLE AU - Max Yates AU - Richard Watts TI - ANCA-associated vasculitis AID - 10.7861/clinmedicine.17-1-60 DP - 2017 Feb 01 TA - Clinical Medicine PG - 60--64 VI - 17 IP - 1 4099 - http://www.rcpjournals.org/content/17/1/60.short 4100 - http://www.rcpjournals.org/content/17/1/60.full SO - Clin Med2017 Feb 01; 17 AB - The vasculitides are a heterogeneous group of conditions typified by their ability to cause vessel inflammation with or without necrosis. They present with a wide variety of signs and symptoms and, if left untreated, carry a significant burden of mortality and morbidity. The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are three separate conditions – granulomatosis with polyangiitis (GPA; formerly known as Wegener’s granulomatosis), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA; previously known as Churg-Strauss syndrome). This review examines recent developments in the pathogenesis and treatment of AAV, focusing on developments in treatment following the introduction of rituximab, in particular.